Thomas Powles, MBBS, MRCP, MD

Vadim Koshkin, MD

GU Oncology Now

<p>Thomas Powles, MBBS, MRCP, MD, Barts Cancer Centre at St. Bartholomew&rsquo;s Hospital, and Vadim Koshkin, MD, University of California, San Francisco, break down the quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis conducted on the JAVELIN Bladder 100 study for the estimated net benefit of avelumab plus best supportive care versus best supportive care alone for patients with advanced urothelial carcinoma.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


Drs. Powles, Koshkin on the Q-TWiST Analysis for JAVELIN Bladder 100

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe